Feb 22, 2024
Vanderbilt University Medical Center is working with scientists around the U.S. to launch the first phase 3, multicenter, placebo-controlled trial to determine the effect of immunomodulation on Long COVID (LC), also known as long-haul COVID or post-acute sequelae of COVID-19. The study is funded by the National Institutes of Health’s National Institute on Aging.